可溶性α-klotho与肝素调节慢性肾脏病中成纤维细胞生长因子23的病理性心脏作用
本研究探讨可溶性α-klotho与肝素对成纤维细胞生长因子23(FGF23)经FGF受体4(FGFR4)介导心肌细胞肥大效应的影响。体外实验显示肝素特异性介导FGF23与FGFR4结合并增强其促心肌细胞肥大与收缩力作用,而可溶性klotho则抑制FGF23诱导的心肌细胞肥大。在两种血清FGF23升高的小鼠模型中,反复注射肝素加重了心脏肥大。
要点
- 肝素特异性介导FGF23与FGFR4结合并增强FGF23对心肌细胞肥大的刺激作用。
- 可溶性klotho对FGF23诱导的心肌细胞肥大发挥抗肥大效应。
- 在血清FGF23升高的小鼠模型中反复注射肝素加重心脏肥大。
核心结论
- 可溶性klotho与肝素作为独立的FGF23共受体,对FGF23的病理性作用产生相反效应:可溶性klotho减轻而肝素加重FGF23诱导的心脏肥大。
- 血液透析中肝素注射是否通过升高FGF23水平参与心血管事件与死亡高发,尚待研究。
研究设计与样本
- 研究建立基于平板的结合实验定量FGF23/FGFR相互作用的亲和力。
- 在分离的心肌细胞中检测可溶性klotho与肝素对FGF23/FGFR4信号及肥大效应的影响。
- 在两种血清FGF23升高的小鼠模型中反复注射肝素观察心脏肥大变化。
- 研究开发了重组可溶性klotho的合成与纯化新方法,并在FGF23处理的心肌细胞中验证其抗肥大效应。
主要发现
- 可溶性klotho与肝素介导FGF23与不同FGFR亚型结合。
- 肝素特异性介导FGF23与FGFR4结合并增强FGF23对分离心肌细胞肥大生长与收缩力的刺激效应。
- 在两种血清FGF23升高的小鼠模型中反复注射肝素加重了心脏肥大。
- 重组可溶性klotho在FGF23处理的心肌细胞中显示出抗肥大效应。
关键数值与推荐
- FGF23通过FGFR4靶向心肌细胞诱导心脏肥大。
- FGF23与FGFR1(肾脏生理性FGF23受体)复合物包含可溶性α-klotho与肝素,二者作为FGF23/FGFR1信号辅因子。
临床怎么用
- 原文未据此给出推荐。
局限性
- 血液透析期间肝素注射在血清FGF23极高的患者中是否促成其高心血管事件与死亡率尚待研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast growth factor (FGF) 23 is a phosphate-regulating hormone that is elevated in patients with chronic kidney disease and associated with cardiovascular mortality. Experimental studies showed that elevated FGF23 levels induce cardiac hypertrophy by targeting cardiac myocytes via FGF receptor isoform 4 (FGFR4). A recent structural analysis revealed that the complex of FGF23 and FGFR1, the physiologic FGF23 receptor in the kidney, includes soluble α-klotho (klotho) and heparin, which both act as co-factors for FGF23/FGFR1 signaling. Here, we investigated whether soluble klotho, a circulating protein with cardio-protective properties, and heparin, a factor that is routinely infused into patients with kidney failure during the hemodialysis procedure, regulate FGF23/FGFR4 signaling and effects in cardiac myocytes. We developed a plate-based binding assay to quantify affinities of specific FGF23/FGFR interactions and found that soluble klotho and heparin mediate FGF23 binding to distinct FGFR isoforms. Heparin specifically mediated FGF23 binding to FGFR4 and increased FGF23 stimulatory effects on hypertrophic growth and contractility in isolated cardiac myocytes. When repetitively injected into two different mouse models with elevated serum FGF23 levels, heparin aggravated cardiac hypertrophy. We also developed a novel procedure for the synthesis and purification of recombinant soluble klotho, which showed anti-hypertrophic effects in FGF23-treated cardiac myocytes. Thus, soluble klotho and heparin act as independent FGF23 co-receptors with opposite effects on the pathologic actions of FGF23, with soluble klotho reducing and heparin increasing FGF23-induced cardiac hypertrophy. Hence, whether heparin injections during hemodialysis in patients with extremely high serum FGF23 levels contribute to their high rates of cardiovascular events and mortality remains to be studied.
引用
- Yanucil C, Kentrup D, Campos I, et al. Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2022. PMID: 35513125. doi:10.1016/j.kint.2022.03.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。